CROs offering Discovery Research with Small Molecule
37 published
37 published CROs match Discovery Research and Small Molecule.
Locations in this set include United States, China, India, United Kingdom, Canada, and France.
Capabilities that show up most often in this set: Medicinal Chemistry, Computational & In-Silico Drug Discovery, High-Throughput Screening, Preclinical In Vitro Studies, and Preclinical In Vivo Studies.
Matching companies
PI Health SciencesPI Health Sciences is an integrated CRDMO offering end-to-end drug discovery, development, and manufacturing services with R&D and manufacturing locations in Europe and India.
Pharma InventorVancouver-based preclinical drug discovery CRO offering medicinal chemistry, custom synthesis, LC-MS/MS bioanalysis, high-throughput screening and ADC development for pharma and biotech teams. Lists 6,000+ sq ft of research facilities and in-house 400 MHz NMR.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PozeSCAF Inc.Preclinical drug discovery CRO combining proprietary generative AI platform AxDrug with computational chemistry, synthetic chemistry, and in vitro biology to accelerate hit discovery and lead optimization for biotech and pharma clients.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.- R2M Pharma, Inc.R2M Pharma is a medicinal chemistry CRO specializing in small-molecule drug discovery and preclinical development, from hit validation through GLP toxicology studies.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
SelvitaSelvita is an integrated drug discovery and development service provider offering comprehensive solutions from target validation through preclinical candidate nomination and clinical manufacturing, with expertise in small molecules, antibodies, and protein degraders.
Sparge Chem Pvt. Ltd.Pune-based provider of custom synthesis, medicinal chemistry, process development, and CRAMS/CDMO services for drug discovery and API intermediates. Offers FTE and fee-for-service engagement models with a 24-hour feasibility response.
Sussex Research Laboratories Inc.Global leader in carbohydrate and glycan synthesis, offering custom synthesis, CRO, and CDMO services for drug discovery and development. Specializes in GalNAc targeting ligands, glycopeptides, and glycoconjugates with over 25 years of expertise.
Sygnature DiscoveryIntegrated drug discovery CRO covering target identification through lead optimization, with computational design, structural biology, medicinal chemistry and DMPK support. Serves biotech and pharma clients across the US, Canada, UK and Europe.
Synfini, Inc.Synfini provides AI-driven drug discovery services from target selection through lead optimization, combining cloud-based AI design tools with robotic wet lab automation to accelerate DMTA cycles across diverse chemical modalities and therapeutic indications.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Veeda LifesciencesVeeda Lifesciences is a contract research organization offering preclinical R&D, BA/BE and bioanalytical studies, and Phase I–IV clinical trials for innovative, biosimilar, and generic drugs. Its capabilities cover both small and large molecules, including clinical bioanalysis and real-world evidence.
VipergenVipergen provides DNA-encoded library (DEL) screening services for hit identification in early-stage drug discovery, offering both in vitro and in-cell selection formats with high-fidelity libraries containing 500+ million drug-like molecules.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/discovery-research/small-molecule.md